Methods for treating obesity and/or metabolic syndrome
The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom.
1. A method for reducing elevated triglycerides or reducing elevated low density lipoproteins or reducing elevated high density lipoproteins or reducing an elevated lipoprotein index or reducing fasting glucose levels or increasing insulin secretion by the pancreas or increasing glucose clearance following feeding or reducing insulin resistance, comprising administering an effective amount of a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom to a subject in need thereof, wherein the subject suffers from excessive weight or obesity.
2. The method of claim 1 , comprising administering an amount of the population enriched for STRO-1 + cells and/or the progeny and/or the soluble factors sufficient to reduce body weight by at least about 3% about 4 weeks after the administration.
3. The method of claim 1 , comprising administering a population of cells enriched for STRO-1 bright cells and/or progeny thereof and/or soluble factors derived therefrom.
4. The method of claim 1 , wherein the population enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom are administered systemically.
5. The method of claim 4 , wherein the population and/or the progeny and/or the soluble factors are administered a plurality of times.
6. The method of claim 5 , wherein the population and/or the progeny and/or the soluble factors are administered once every four or more weeks.
7. The method of claim 1 , comprising administering between 0.1×10 6 to 5×10 6 STRO-1 + cells and/or progeny thereof per kg.
8. The method of claim 7 , comprising administering between 0.3×10 6 to 2×10 6 STRO-1 + cells and/or progeny thereof per kg.
9. The method of claim 1 , comprising administering a low dose of STRO-1 + cells and/or progeny thereof.
10. The method of claim 9 , wherein the low dose of STRO-1 + cells and/or progeny thereof comprises between 0.1×10 5 and 0.5×10 6 STRO-1 + cells and/or progeny thereof per kg.
11. The method of claim 9 , wherein the low dose of STRO-1 + cells and/or progeny thereof comprises about 0.3×10 6 STRO-1 + cells and/or progeny thereof per kg.
12. The method of claim 1 , wherein the population enriched for STRO-1 + cells and/or progeny cells are autogeneic or allogeneic and/or the soluble factors can be derived from autogeneic or allogeneic cells.
13. The method of claim 12 , wherein the population enriched for STRO-1 + cells and/or progeny cells have been culture expanded prior to administration and/or prior to obtaining the soluble factors.
14. The method of claim 1 , wherein the population enriched for STRO-1 + cells are STRO-1 bri , and/or express tissue non-specific alkaline phosphatase (TNAP) and/or the progeny cells and/or soluble factors are derived from STRO-1 + cells that are STRO-1 bri and/or express TNAP.
15. The method of claim 1 , wherein the STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom are administered in the form of a composition comprising said STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom and a carrier and/or excipient.